Skip to content
Screener

ANI Pharmaceuticals ANIP Other Income (Expense)

Other Income (Expense) at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
-$58.78M+1.5%
Viatris logo
ViatrisVTRS
$50.4M+115%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$18.21M-55.0%
ALN
Alnylam PharmaceuticalsALNY
-$53.64M-180%
PVL
Palvella TherapeuticsPVLA
-$32K-114%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$3.98M-103%

Segments

By segment

See full
Generics and Other$0
Rare Disease and Brands$0

Other financials

Income statement

See full
Revenue$266.0M+25.9%
Gross profit$165.9M+21.3%
Operating income$40.5M+191%
Net income$24.7M+189%
EPS (diluted)$1.05+192%

Balance sheet

See full
Cash & equivalents$360.2M+65.4%
Total debt$301.5M-4.2%
Total equity$597.2M+36.7%
Total assets$1.5B+11.3%

Cash flow

See full
Operating cash flow$56.7M-25.3%
CapEx$3.1M-23.9%
Free cash flow$53.6M-25.3%

Valuation

See full
Market cap$1.88B+25.6%
Enterprise value$1.82B+14.3%
P/E17.3×
P/S1.9×-0.1×

Profitability

See full
Gross margin60.4%-0.7pp
Operating margin15.4%
Net margin11.1%+10.0pp
FCF margin17.7%+0.9pp

Returns & leverage

See full
Return on equity21%+19.1pp
Debt / equity0.5×-0.2×
Current ratio2.9×+0.4×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 7:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001023024-26-000069
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other (expense) income, net
Unrealized gain (loss) on investment in equity securities7413326,494(589)
Interest expense, net(3,636)(5,438)(7,405)(10,922)
Other (expense) income, net(468)1,739(1,119)1,937
Income Before Income Tax Expense37,09710,52577,31830,512
Income tax expense12,3861,97623,1156,282
Net Income$24,711$8,549$54,203$24,230
Dividends on Series A Convertible Preferred Stock(407)(813)

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is ANI Pharmaceuticals's other income (expense)?
ANI Pharmaceuticals (ANIP) reported other income (expense) of -$468K in Q2 2026.
How has ANI Pharmaceuticals's other income (expense) changed year-over-year?
ANI Pharmaceuticals's other income (expense) decreased by 126.9% year-over-year, from $1.74M to -$468K.
What is the long-term trend for ANI Pharmaceuticals's other income (expense)?
Over 4 years (2021 to 2025), ANI Pharmaceuticals's other income (expense) has grown at a -18.3% compound annual growth rate (CAGR), from -$4.34M to $1.93M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about ANI Pharmaceuticals's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude